Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants | Zendy

Aline Barth | Zendy; Mohammad Hossain | Zendy; Darin Brimhall | Zendy; Caroline Perry | Zendy; Courtney Tiffany | Zendy; Sherry L. Xu | Zendy; Étienne Dumont | Zendy

Open Access

Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants

Author(s) -

Aline Barth,

Mohammad Hossain,

Darin Brimhall,

Caroline Perry,

Courtney Tiffany,

Sherry L. Xu,

Étienne Dumont

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01263-21

Subject(s) - pharmacokinetics , topoisomerase , pharmacology , medicine , microbiology and biotechnology , biology , genetics , dna

Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that may provide a new treatment option for antibiotic-resistant pathogens. Two pharmacokinetic evaluations of oral gepotidacin are presented: a relative bioavailability study that guided formulation development, followed by an adult and adolescent study of the final formulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research